Adma Biologics reported $73.9M in Sales Revenues for its fiscal quarter ending in December of 2023.

Sales Change Date
Adma Biologics USD 73.9M 6.63M Dec/2023
Alnylam Pharmaceuticals USD 494.33M 54.61M Mar/2024
Dynavax Technologies USD 50.79M 18.72M Mar/2024
Takeda JPY 1.05T 60.28B Mar/2024